Stage 3 or worse chronic kidney disease
There is 1 paper on stage 3 or worse chronic kidney disease in aging research: 1 observational study in people.
1 paper studies it3 findings
1 new paper in 30 daysSee all 1
“Alogliptin was associated with lower risk of stage 3 or worse CKD than linagliptin (hazard ratio [HR] 0.50; 95% CI 0.37-0.69)”
- Humans1
Associations
3Linagliptin
upin humans1HR 1.15
1 study
Linagliptin
upin humans1HR 1.15
Linagliptin is associated with stage 3 or worse chronic kidney disease in humans (HR 1.15; 95% CI 1.10-1.21 versus sitagliptin).
“Conversely, linagliptin was associated with higher risk than sitagliptin (HR 1.15, 95% CI 1.10-1.21).”
HumansType 2 diabetes with moderate cardiovascular risk and without baseline stage 3 or worse chronic kidney disease; compared with sitagliptin
Diabetes, obesity, and cardiometabolic CARE
Saxagliptin
downin humans1HR 0.8
1 study
Saxagliptin
downin humans1HR 0.8
Saxagliptin is associated with stage 3 or worse chronic kidney disease in humans (HR 0.80; 95% CI 0.73-0.87 versus linagliptin).
“saxagliptin was associated with lower risk than linagliptin (HR 0.80; 95% CI 0.73-0.87).”
HumansType 2 diabetes with moderate cardiovascular risk and without baseline stage 3 or worse chronic kidney disease; compared with linagliptin
Diabetes, obesity, and cardiometabolic CARE
Alogliptin
downin humans1HR 0.5
1 study
Alogliptin
downin humans1HR 0.5
Alogliptin is associated with stage 3 or worse chronic kidney disease in humans (HR 0.50; 95% CI 0.37-0.69 versus linagliptin).
“Alogliptin was associated with lower risk of stage 3 or worse CKD than linagliptin (hazard ratio [HR] 0.50; 95% CI 0.37-0.69)”
HumansType 2 diabetes with moderate cardiovascular risk and without baseline stage 3 or worse chronic kidney disease; compared with linagliptin
Diabetes, obesity, and cardiometabolic CARE